Global Orphan Indication Drugs 麻豆原创 Growth 2025-2031

Publication ID:

LPI03257631

Publication Date:

March 4, 2025

Pages:

113

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Orphan Indication Drugs market size is predicted to grow from US$ 653 million in 2025 to US$ 753 million in 2031; it is expected to grow at a CAGR of 2.4% from 2025 to 2031.
An orphan drug is a drug used to treat a disease that cannot be produced profitably without government assistance because of the small number of patients.The classification of certain diseases, and the medicines that treat them, as "orphan" is a matter of public policy in many countries . Given the nature of the enormous economic resources required for medical research , these medicines would have no chance of producing breakthroughs that otherwise might not have been possible without government assistance.In the United States and the European Union , orphan drugs are easier to obtain marketing authorization. There may also be additional financial incentives, such as an extension of the market exclusivity period, which would allow the pharmaceutical company to have a longer exclusivity to sell the drug. All of these measures are designed to encourage drug development, and without this kind of profit motive , few pharmaceutical companies will be willing to allocate their budgets and personnel to this type of research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The 鈥淥rphan Indication Drugs Industry Forecast鈥� looks at past sales and reviews total world Orphan Indication Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Orphan Indication Drugs sales for 2025 through 2031. With Orphan Indication Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Orphan Indication Drugs industry.
This Insight Report provides a comprehensive analysis of the global Orphan Indication Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Orphan Indication Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Orphan Indication Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Orphan Indication Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Orphan Indication Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Orphan Indication Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Biologics
Non-Biologics
Segmentation by Application:
Hospital Pharmacy
Retail Pharmacy
Online Sales
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Bristol-Myers Squibb
Roche
Novartis
Johnson & Johnson
Pfizer
Amgen
Sanofi
AstraZeneca
Takeda
Vertex Pharmaceuticals
AbbVie
Biogen
Eli Lilly
Key Questions Addressed in this Report
What is the 10-year outlook for the global Orphan Indication Drugs market?
What factors are driving Orphan Indication Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Orphan Indication Drugs market opportunities vary by end market size?
How does Orphan Indication Drugs break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Orphan Indication Drugs Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Orphan Indication Drugs by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Orphan Indication Drugs by Country/Region, 2020, 2024 & 2031
2.2 Orphan Indication Drugs Segment by Type
2.2.1 Biologics
2.2.2 Non-Biologics
2.3 Orphan Indication Drugs Sales by Type
2.3.1 Global Orphan Indication Drugs Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Orphan Indication Drugs Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Orphan Indication Drugs Sale Price by Type (2020-2025)
2.4 Orphan Indication Drugs Segment by Application
2.4.1 Hospital Pharmacy
2.4.2 Retail Pharmacy
2.4.3 Online Sales
2.5 Orphan Indication Drugs Sales by Application
2.5.1 Global Orphan Indication Drugs Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Orphan Indication Drugs Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Orphan Indication Drugs Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Orphan Indication Drugs Breakdown Data by Company
3.1.1 Global Orphan Indication Drugs Annual Sales by Company (2020-2025)
3.1.2 Global Orphan Indication Drugs Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Orphan Indication Drugs Annual Revenue by Company (2020-2025)
3.2.1 Global Orphan Indication Drugs Revenue by Company (2020-2025)
3.2.2 Global Orphan Indication Drugs Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Orphan Indication Drugs Sale Price by Company
3.4 Key Manufacturers Orphan Indication Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Orphan Indication Drugs Product Location Distribution
3.4.2 Players Orphan Indication Drugs Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Orphan Indication Drugs by Geographic Region
4.1 World Historic Orphan Indication Drugs 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Orphan Indication Drugs Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Orphan Indication Drugs Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Orphan Indication Drugs 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Orphan Indication Drugs Annual Sales by Country/Region (2020-2025)
4.2.2 Global Orphan Indication Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Orphan Indication Drugs Sales Growth
4.4 APAC Orphan Indication Drugs Sales Growth
4.5 Europe Orphan Indication Drugs Sales Growth
4.6 Middle East & Africa Orphan Indication Drugs Sales Growth
5 Americas
5.1 Americas Orphan Indication Drugs Sales by Country
5.1.1 Americas Orphan Indication Drugs Sales by Country (2020-2025)
5.1.2 Americas Orphan Indication Drugs Revenue by Country (2020-2025)
5.2 Americas Orphan Indication Drugs Sales by Type (2020-2025)
5.3 Americas Orphan Indication Drugs Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Orphan Indication Drugs Sales by Region
6.1.1 APAC Orphan Indication Drugs Sales by Region (2020-2025)
6.1.2 APAC Orphan Indication Drugs Revenue by Region (2020-2025)
6.2 APAC Orphan Indication Drugs Sales by Type (2020-2025)
6.3 APAC Orphan Indication Drugs Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Orphan Indication Drugs by Country
7.1.1 Europe Orphan Indication Drugs Sales by Country (2020-2025)
7.1.2 Europe Orphan Indication Drugs Revenue by Country (2020-2025)
7.2 Europe Orphan Indication Drugs Sales by Type (2020-2025)
7.3 Europe Orphan Indication Drugs Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Orphan Indication Drugs by Country
8.1.1 Middle East & Africa Orphan Indication Drugs Sales by Country (2020-2025)
8.1.2 Middle East & Africa Orphan Indication Drugs Revenue by Country (2020-2025)
8.2 Middle East & Africa Orphan Indication Drugs Sales by Type (2020-2025)
8.3 Middle East & Africa Orphan Indication Drugs Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Orphan Indication Drugs
10.3 Manufacturing Process Analysis of Orphan Indication Drugs
10.4 Industry Chain Structure of Orphan Indication Drugs
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Orphan Indication Drugs Distributors
11.3 Orphan Indication Drugs Customer
12 World Forecast Review for Orphan Indication Drugs by Geographic Region
12.1 Global Orphan Indication Drugs 麻豆原创 Size Forecast by Region
12.1.1 Global Orphan Indication Drugs Forecast by Region (2026-2031)
12.1.2 Global Orphan Indication Drugs Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Orphan Indication Drugs Forecast by Type (2026-2031)
12.7 Global Orphan Indication Drugs Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Bristol-Myers Squibb
13.1.1 Bristol-Myers Squibb Company Information
13.1.2 Bristol-Myers Squibb Orphan Indication Drugs Product Portfolios and Specifications
13.1.3 Bristol-Myers Squibb Orphan Indication Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Bristol-Myers Squibb Main Business Overview
13.1.5 Bristol-Myers Squibb Latest Developments
13.2 Roche
13.2.1 Roche Company Information
13.2.2 Roche Orphan Indication Drugs Product Portfolios and Specifications
13.2.3 Roche Orphan Indication Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Roche Main Business Overview
13.2.5 Roche Latest Developments
13.3 Novartis
13.3.1 Novartis Company Information
13.3.2 Novartis Orphan Indication Drugs Product Portfolios and Specifications
13.3.3 Novartis Orphan Indication Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Novartis Main Business Overview
13.3.5 Novartis Latest Developments
13.4 Johnson & Johnson
13.4.1 Johnson & Johnson Company Information
13.4.2 Johnson & Johnson Orphan Indication Drugs Product Portfolios and Specifications
13.4.3 Johnson & Johnson Orphan Indication Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Johnson & Johnson Main Business Overview
13.4.5 Johnson & Johnson Latest Developments
13.5 Pfizer
13.5.1 Pfizer Company Information
13.5.2 Pfizer Orphan Indication Drugs Product Portfolios and Specifications
13.5.3 Pfizer Orphan Indication Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Pfizer Main Business Overview
13.5.5 Pfizer Latest Developments
13.6 Amgen
13.6.1 Amgen Company Information
13.6.2 Amgen Orphan Indication Drugs Product Portfolios and Specifications
13.6.3 Amgen Orphan Indication Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Amgen Main Business Overview
13.6.5 Amgen Latest Developments
13.7 Sanofi
13.7.1 Sanofi Company Information
13.7.2 Sanofi Orphan Indication Drugs Product Portfolios and Specifications
13.7.3 Sanofi Orphan Indication Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Sanofi Main Business Overview
13.7.5 Sanofi Latest Developments
13.8 AstraZeneca
13.8.1 AstraZeneca Company Information
13.8.2 AstraZeneca Orphan Indication Drugs Product Portfolios and Specifications
13.8.3 AstraZeneca Orphan Indication Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 AstraZeneca Main Business Overview
13.8.5 AstraZeneca Latest Developments
13.9 Takeda
13.9.1 Takeda Company Information
13.9.2 Takeda Orphan Indication Drugs Product Portfolios and Specifications
13.9.3 Takeda Orphan Indication Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Takeda Main Business Overview
13.9.5 Takeda Latest Developments
13.10 Vertex Pharmaceuticals
13.10.1 Vertex Pharmaceuticals Company Information
13.10.2 Vertex Pharmaceuticals Orphan Indication Drugs Product Portfolios and Specifications
13.10.3 Vertex Pharmaceuticals Orphan Indication Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Vertex Pharmaceuticals Main Business Overview
13.10.5 Vertex Pharmaceuticals Latest Developments
13.11 AbbVie
13.11.1 AbbVie Company Information
13.11.2 AbbVie Orphan Indication Drugs Product Portfolios and Specifications
13.11.3 AbbVie Orphan Indication Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 AbbVie Main Business Overview
13.11.5 AbbVie Latest Developments
13.12 Biogen
13.12.1 Biogen Company Information
13.12.2 Biogen Orphan Indication Drugs Product Portfolios and Specifications
13.12.3 Biogen Orphan Indication Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Biogen Main Business Overview
13.12.5 Biogen Latest Developments
13.13 Eli Lilly
13.13.1 Eli Lilly Company Information
13.13.2 Eli Lilly Orphan Indication Drugs Product Portfolios and Specifications
13.13.3 Eli Lilly Orphan Indication Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Eli Lilly Main Business Overview
13.13.5 Eli Lilly Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.